Skip to main
  1. Stocks
  2. Progyny
  3. Forecast
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is supported by strong fundamentals, including Q3 revenue of $341.3M and EBITDA of $58.4M, both slightly ahead of consensus, while fertility revenue grew 11% Y/Y and pharmacy revenue rose 6% Y/Y. The company’s record 2027 selling season added 1.3M covered lives, with retention near 100%, more than 85 new clients expected, and over 3M lives slated for expanded product access, signaling durable demand and share gains across industries. Its attractive outlook is further reinforced by $57M of Q3 operating cash flow, aggressive share repurchases, and management’s repeated guidance raises, which together highlight a scalable business with strong cash generation and disciplined execution.

Bears say

Progyny is facing a fundamentally pressured outlook because its utilization-driven model can swing sharply quarter to quarter, making revenue visibility weak and leaving estimates vulnerable if attrition rises, utilization softens, or new solution revenue arrives more slowly than expected. Its growth is also tied to employment levels and employer benefit decisions, so an economic downturn or delayed customer adds could reduce membership, while a volatile political backdrop around reproductive rights may further dampen demand for its fertility services. Competitive intensity is worsening from traditional carriers and well-funded carve-out rivals, and operational risks in pharmacy supply and physician network quality could impair service delivery and contribute to the loss of large customers.

Progyny (PGNY) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Progyny (PGNY) Analyst Forecast & Price Prediction

Get the latest Progyny (PGNY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Progyny (PGNY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 11 analysts, Progyny (PGNY) has a Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Progyny (PGNY) Analyst Forecast & Price Prediction

Get the latest Progyny (PGNY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Progyny (PGNY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PGNY stock data and trends